• Hyperlipoproteinemias

Zypitamag Generic Name & Formulations

General Description

Pitavastatin 2mg, 4mg; tabs.

Pharmacological Class

HMG-CoA reductase inhibitor.

How Supplied

Tabs—30, 90, 100, 500, 1000


Generic Availability


Zypitamag Indications


Adjunct to diet to reduce elevated total-C, LDL-C, ApoB, and TG, and to increase HDL-C in primary hyperlipidemia and mixed dyslipidemia.

Limitations of Use

Effect on cardiovascular morbidity and mortality has not been determined.

Zypitamag Dosage and Administration


Individualize. Initially 2mg once daily; may increase after 4 weeks to max 4mg once daily. Moderate to severe renal impairment (CrCl 15–59mL/min, or ESRD with hemodialysis): initially 1mg once daily; max 2mg once daily. Concomitant erythromycin: max 1mg daily. Concomitant rifampin: max 2mg daily.


Not established.

Zypitamag Contraindications


Active liver disease. Unexplained, persistent elevated serum transaminases. Concomitant cyclosporine. Pregnancy. Nursing mothers.

Zypitamag Boxed Warnings

Not Applicable

Zypitamag Warnings/Precautions


Increased risk of myopathy and rhabdomyolysis esp. in renal impairment, uncontrolled hypothyroidism, age ≥65yrs, higher dose. Discontinue if markedly elevated CK levels occur or myopathy is confirmed or suspected; suspend if a predisposition to development of renal failure secondary to rhabdomyolysis develops. Immune-mediated necrotizing myopathy; monitor. Monitor liver function prior to initiation and as clinically indicated. Discontinue immediately if serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs. Substantial alcohol ingestion. Advise females of reproductive potential to use effective contraception during treatment.

Zypitamag Pharmacokinetics

See Literature

Zypitamag Interactions


See Contraindications. Avoid gemfibrozil. Potentiated by erythromycin, rifampin (see Adults). Increased risk of myopathy with concomitant fibrates, colchicine, niacin (≥1g/day); consider risk/benefit.

Zypitamag Adverse Reactions

Adverse Reactions

Myalgia, back/extremity pain, diarrhea, constipation; myopathy, rhabdomyolysis, increases in CK, liver enzymes, HbA1c and fasting serum glucose; rare: cognitive impairment, fatal/non-fatal hepatic failure.

Zypitamag Clinical Trials

See Literature

Zypitamag Note

Not Applicable

Zypitamag Patient Counseling

See Literature